Nano-anticancer drug, targeted carrier and preparation method combining chemotherapy, photothermal therapy and radiotherapy
The mitochondrial targeting vector mediated by GLUT1 and responding to hypoxia solves the problem of low targeting efficiency of existing tumor-targeting drugs, achieves efficient uptake by tumor cells and synergistic therapeutic effects, and enhances the tumor-killing ability of chemotherapy, photothermal therapy and radiotherapy.
CN119548625BActive Publication Date: 2026-06-19CHINA INST FOR RADIATION PROTECTION
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHINA INST FOR RADIATION PROTECTION
- Filing Date
- 2024-12-03
- Publication Date
- 2026-06-19
Smart Images
Figure BDA0005168170170000081 
Figure BDA0005168170170000091 
Figure BDA0005168170170000101
Abstract
This invention relates to nano-anticancer drugs, targeting carriers, and preparation methods that combine chemotherapy, photothermal therapy, and radiotherapy. First, Azo is coupled to Glu-PEG-NHS and modified with carboxyl groups to obtain a Glu-PEG-Azo-COOH derivative. Then, mitochondrial targeting group TPP and photothermal agent IR808 are modified onto the surface of PAMAM to obtain Mito. 808 Then, the Glu-PEG-Azo conjugate was combined with Mito 808 By coupling, a targeting carrier is obtained, and then anti-tumor drugs and radionuclides are loaded through electrostatic adsorption to obtain nano-anticancer drugs. This invention achieves GLUT1 targeting, improves the uptake of tumor cells, and can also shield the positive charge of TPP, prolong the in vivo circulation time, enhance the stability of in vivo circulation, and in the hypoxic microenvironment of tumors, it can remove PEG derivatives to expose the mitochondrial targeting group TPP, thereby achieving mitochondrial targeting.
Need to check novelty before this filing date? Find Prior Art